Literature DB >> 2821680

Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect.

D C Montefiori1, W M Mitchell.   

Abstract

We previously demonstrated a high permissiveness of HTLV-II-transformed T lymphocytes (C3) to human immunodeficiency virus (HIV) infection in vitro, and that this infection results in the lysis of cells (D.C. Montefiori and W.M. Mitchell (1986) Virology 155, 726-731). We now show that a small percentage of HIV-infected C3 cells resist cell lysis, grow continuously in culture, and express antigens of both viruses. High levels of reverse transcriptase activity found in the culture fluid of these coinfected cells were associated with the presence of fully infectious HIV and an absence of detectable infectious HTLV-II. Virus production in C3 cells coinfected with the HIV isolate HTLV-III was approximately threefold greater than in C3 cells coinfected with the HIV isolate LAV, a result which suggests that HIV genomic diversity may give rise to differences in replicative capacities. Lysis resistance was found to be a cellular-determined function in that HIV produced in cultures of C3/HTLV-III cells retained the capacity to elicit a lytic response upon repeated infection. Small syncytia (less than five nuclei) were rarely observed in cultures of C3 and nonlytic C3/HIV cells, whereas large syncytia (more than five nuclei) were in abundance during the lytic phase of coinfection, a result which supports a role for syncytium formation in the mechanism of HIV-induced cytopathic effects. The results of these studies further demonstrate that there exists a lack of viral interference by HTLV-II infection, and that HTLV-II-transformed lymphocytes could act as a chronic reservoir for HIV in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821680     DOI: 10.1016/0042-6822(87)90008-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  CD4-independent infection by human immunodeficiency virus type 1 after phenotypic mixing with human T-cell leukemia viruses.

Authors:  P Lusso; F Lori; R C Gallo
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Reciprocal functional pseudotyping of HIV-1 and HTLV-1 viral genomes by the heterologous counterpart envelope proteins.

Authors:  Zachary Klase; Kuan-Teh Jeang
Journal:  Virology       Date:  2013-06-05       Impact factor: 3.616

3.  Antifusion activity in sera from persons infected with human immunodeficiency virus type 1.

Authors:  B S Graham; J M Rowland; A Modliszewski; D C Montefiori
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

4.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction.

Authors:  C R Wyatt; D Wingett; J S White; C D Buck; D Knowles; R Reeves; N S Magnuson
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

6.  Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; M K Gorny; D Lake; J Y Xu; Y Matsumoto; T Sugano; Y Masuho; W M Mitchell; E Hersh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Pseudotyping of HIV-1 with Human T-Lymphotropic Virus 1 (HTLV-1) Envelope Glycoprotein during HIV-1-HTLV-1 Coinfection Facilitates Direct HIV-1 Infection of Female Genital Epithelial Cells: Implications for Sexual Transmission of HIV-1.

Authors:  Yuyang Tang; Alvin M George; Oksana Petrechko; Franklin J Nouvet; Stephanie D Sweet; Yuetsu Tanaka; Brian S Imbiakha; Guochun Jiang; Wei Gao; Kathryn Anastos; James E K Hildreth
Journal:  mSphere       Date:  2018-04-04       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.